Skip to main content

Drug Interactions between Kengreal and ticlopidine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ticlopidine cangrelor

Applies to: ticlopidine and Kengreal (cangrelor)

MONITOR CLOSELY: Concomitant use of cangrelor with anticoagulants, thrombolytic agents, or other antiplatelet agents may theoretically increase the risk of bleeding. According to the manufacturer, cangrelor has been formally studied with unfractionated heparin and aspirin in healthy study subjects with no evidence of a pharmacokinetic or pharmacodynamic interaction. In clinical trials, cangrelor has been coadministered with bivalirudin, low molecular weight heparin, clopidogrel, prasugrel, and ticagrelor without clinically detectable interactions.

MANAGEMENT: Caution is recommended if cangrelor must be used in patients treated with other agents that alter hemostasis. Patients should be monitored for potentially increased bleeding complications.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2015) "Product Information. Kengreal (cangrelor)." The Medicines Company

Drug and food interactions

Moderate

ticlopidine food

Applies to: ticlopidine

ADJUST DOSING INTERVAL: The bioavailability and gastrointestinal tolerance of ticlopidine is enhanced by food.

MANAGEMENT: Patients may be advised to take ticlopidine with meals.

References (1)
  1. (2001) "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Adp receptor antagonists

Therapeutic duplication

The recommended maximum number of medicines in the 'ADP receptor antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ADP receptor antagonists' category:

  • Kengreal (cangrelor)
  • ticlopidine

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer